Last reviewed · How we verify
Cytokine Release Syndrome
Approved treatments
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
- tocilizumab or sarilumab · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Cytokine Release Syndrome patent landscape — cliff calendar, originator estates, attackable patents
- Cytokine Release Syndrome treatment landscape brief
- Cytokine Release Syndrome treatment updates RSS
Frequently asked questions about Cytokine Release Syndrome
What drugs treat Cytokine Release Syndrome?
Tracked treatments include tocilizumab or sarilumab.
What is the treatment for Cytokine Release Syndrome?
Standard treatment for Cytokine Release Syndrome includes tocilizumab or sarilumab. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Cytokine Release Syndrome patent cliff · Cytokine Release Syndrome CI report
- Treatment: tocilizumab or sarilumab · Pfizer
- Treatment: tocilizumab or sarilumab · Pfizer
- Treatment: tocilizumab or sarilumab · Pfizer
- Treatment: tocilizumab or sarilumab · Pfizer
- Treatment: tocilizumab or sarilumab · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing